NIH Director: Defeating COVID-19 requires unprecedented action and collaboration

To respond to the generational public health crisis caused by the global COVID-19 pandemic, a swift, coordinated effort across many sectors of society is necessary, say National Institutes of Health (NIH) Director Francis S. Collins, M.D., Ph.D., and Johnson & Johnson Vice Chairman of the Executive Committee and Chief Scientific Officer Paul Stoffels, M.D. In a Viewpoint published today in JAMA(link is external), Drs. Collins and Stoffels outline the innovative efforts of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private initiative organized by NIH and the Foundation for the NIH. ACTIV’s partners, which include at least 18 leading biopharmaceutical companies, multiple U.S. federal agencies, and the European Medicines Agency, are developing an international strategy for an integrated research response to COVID-19.

Noting that never has a public-private biomedical research effort of this scope and scale come together with such speed and determination, Drs. Collins and Stoffels describe how ACTIV has established a collaborative framework to prioritize therapeutic and vaccine candidates; to streamline human clinical trials and tap into existing trial networks; and to coordinate regulatory processes and leverage assets among all partners. The authors point out that ACTIV’s industry partners have taken unprecedented steps to support a prioritization of therapeutic and vaccine candidates, no matter who has developed them, and have indicated willingness to contribute their respective clinical trial capacities, irrespective of the agent to be studied.

ACTIV has established four working groups, each with one co-chair from NIH and one from industry. They are:

  • The Preclinical Working Group. Charged with standardizing and sharing preclinical evaluation resources and methods, and with accelerating testing of candidate therapies and vaccines to support entry into clinical trials.
  • The Therapeutics Clinical Working Group. Charged with prioritizing and accelerating clinical evaluation of a long list of therapeutic candidates for COVID-19 with near-term potential.
  • The Clinical Trial Capacity Working Group. Charged with assembling and coordinating existing networks of clinical trials to increase efficiency and build capacity to test potential therapies and vaccines for COVID-19.
  • The Vaccines Working Group. Charged with accelerating evaluation of vaccine candidates to enable rapid authorization or approval.

Article

Collins FS, Stoffels P. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times(link is external). JAMA. DOI: 10.1001/jama.2020.8920 (2020).


The material in this press release comes from the originating research organization. Content may be edited for style and length. Have a question? Let us know.

Subscribe

One email, each morning, with our latest posts. From medical research to space news. Environment to energy. Technology to physics.

Thank you for subscribing.

Something went wrong.

1 thought on “NIH Director: Defeating COVID-19 requires unprecedented action and collaboration”

  1. Another approach involves recognizing and eliminating the deadly features of the coronavirus and letting the milder version infect you, allowing your body to develop a self-vaccine against the deadly version.

    My investigations found three one-in-a-million nucleotide matches between the coronavirus and the human genome as a loop in tRNA, a major component in producing proteins within the cell. I speculate that at least one of those sequences is making the coronavirus more deadly. Perhaps eliminating them in the virus may allow our immune system to produce a self-immunity. Testing this speculation must be done and is described in a YouTube titled “Coronavirus – Using Your DNA Against You” at https://www.youtube.com/watch?v=1iZ1ohdpxbI

    Reply

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.